August 25, 2021 -- Athos Therapeutics and the Cleveland Clinic have agreed to collaborate on inflammatory bowel disease (IBD) research. The agreement will advance the use of systems biology and computational science for precision medicine in inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
Using a systems biology approach can enable clinicians to properly characterize the heterogeneity of the disease at the molecular level, the companies believe. From there, IBD patients can be classified into specific molecular subtypes, enabling the development of custom-made therapies.
Financial details of the collaboration were not disclosed.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: